Overview

EPI-743 in Friedreich's Ataxia Point Mutations

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of EPI-743 in patients with Friedreich's Ataxia point mutations
Phase:
Phase 2
Details
Lead Sponsor:
University of South Florida
Collaborators:
Edison Pharmaceuticals Inc
Friedreich's Ataxia Research Alliance
Treatments:
Tocopherols
Tocotrienol, alpha
Tocotrienols
Ubiquinone
Vitamin E